Anticorpo monoclonal isolado anti-molécula de orientação repulsiva a

anticorpos monoclonais contra proteina rgm a e usos destes. a presente invenção refere-se a proteínas isoladas, particularmente anticorpos monocionais, que ligam e neutralizam a proteína rgm a. de modo específico, esses anticorpos têm a capacidade de inibirem a ligação de rgm a a seu receptor e/ou c...

Full description

Saved in:
Bibliographic Details
Main Authors Eve H. Barlow, Hsieh Chungming, Bernhard K. Müller, Phillip D. Bardwell, Schmidt Martin, Mary R. Leddy
Format Patent
LanguagePortuguese
Published 15.03.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract anticorpos monoclonais contra proteina rgm a e usos destes. a presente invenção refere-se a proteínas isoladas, particularmente anticorpos monocionais, que ligam e neutralizam a proteína rgm a. de modo específico, esses anticorpos têm a capacidade de inibirem a ligação de rgm a a seu receptor e/ou co-receptores. esses anticorpos ou porções destes da invenção são úteis para determinar rgm a e inibir a atividade de rgm a, por exemplo, em um individuo que sofre de um distúrbio que inclui, mas não se limita a, esclerose múltipla, trauma cerebral de mamíferos, lesão da medula espinhal, derrame, doenças neurodegenerativas e esquizofrenia. The subject invention relates to monoclonal antibodies which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or antigen binding fragments thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but not limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.
AbstractList anticorpos monoclonais contra proteina rgm a e usos destes. a presente invenção refere-se a proteínas isoladas, particularmente anticorpos monocionais, que ligam e neutralizam a proteína rgm a. de modo específico, esses anticorpos têm a capacidade de inibirem a ligação de rgm a a seu receptor e/ou co-receptores. esses anticorpos ou porções destes da invenção são úteis para determinar rgm a e inibir a atividade de rgm a, por exemplo, em um individuo que sofre de um distúrbio que inclui, mas não se limita a, esclerose múltipla, trauma cerebral de mamíferos, lesão da medula espinhal, derrame, doenças neurodegenerativas e esquizofrenia. The subject invention relates to monoclonal antibodies which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or antigen binding fragments thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but not limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.
Author Eve H. Barlow
Schmidt Martin
Mary R. Leddy
Hsieh Chungming
Bernhard K. Müller
Phillip D. Bardwell
Author_xml – fullname: Eve H. Barlow
– fullname: Hsieh Chungming
– fullname: Bernhard K. Müller
– fullname: Phillip D. Bardwell
– fullname: Schmidt Martin
– fullname: Mary R. Leddy
BookMark eNqNyjsOwjAMgOEMMPC6gxfGSk3aC7SIx4zYKys1UiTXjpqWCzEgzpGLwcABmP7h-9dmISq0MudGpuB1jAqDinpWQYaQlLFXwC8Wg3J--5kRegIdA8mE-ZWfCiPFmVN4IODWLO_IiXa_bsz-dLwdLgVF7ShF9CQ0de3VOldaV5Z1VdvWVv9-H062OXo
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID BR122012004341B1
GroupedDBID EVB
ID FETCH-epo_espacenet_BR122012004341B13
IEDL.DBID EVB
IngestDate Fri Jul 19 14:22:09 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Portuguese
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_BR122012004341B13
Notes Application Number: BR20121204341
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220315&DB=EPODOC&CC=BR&NR=122012004341B1
ParticipantIDs epo_espacenet_BR122012004341B1
PublicationCentury 2000
PublicationDate 20220315
PublicationDateYYYYMMDD 2022-03-15
PublicationDate_xml – month: 03
  year: 2022
  text: 20220315
  day: 15
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies ABBVIE INC
ABBOTT LABORATORIES
ABBOTT GMBH & CO. KG
RelatedCompanies_xml – name: ABBOTT LABORATORIES
– name: ABBVIE INC
– name: ABBOTT GMBH & CO. KG
Score 3.235834
Snippet anticorpos monoclonais contra proteina rgm a e usos destes. a presente invenção refere-se a proteínas isoladas, particularmente anticorpos monocionais, que...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title Anticorpo monoclonal isolado anti-molécula de orientação repulsiva a
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220315&DB=EPODOC&locale=&CC=BR&NR=122012004341B1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhR1dS8Mw8BhT1Dedip8jD9q3Iu2SbX0oYtvVIeyDMmVvI21TKNSmbJ3-IB_E37E_5qVsfrzoW0jCkVzucrnLfQBcJaFgrVgw3bI41SljXOecos7TZibtWkkUJcoOORi2-4_0YcqmNcg3sTBVntDXKjkiclSE_F5W93XxbcTyKt_KxU2YYpe89Se2p621Y9NURQs0z7F745E3cjXXtZ1AGwa2gUOGogi8tR3UlrbUU1rl2u89OSoypfgpVvx92B4jxLw8gFpRNmDX3VRfa8DOYP3pjc01_y0O4f4ux4NWyYcJko-MMvWOJinSD48lQSSl-rPMVh_KuZTEgsh5Fe64el-9STIXxTJbpC-c8CO49nsTt6_jimZfKJg5we8NtI6hnstcnABhgoc85i3DSAQ1uRXGyII0CdsoiDuduHsKzb9hnf034Rz2FGqV55XBLqBezpfiEkVxGTYr_H0ClQKOnQ
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhR3LTsMwzJoGYtxggHiOHKC3CrVLtvVQIdpuDNhL00C7TWmbSpVGU20dfBAHxHfsx3CqjccFblESWYljx7HjB8BF5AtWDQXTLYtTnTLGdc4p6jw1ZtKGFQVBpOyQ3V6t_Ujvx2xcgGQdC5PnCX3NkyMiRwXI71l-X6ffRiwv962cX_kxdsnr1sj2tJV2bJqqaIHmOXZz0Pf6rua6tjPUekPbwCFDUQTe2g5qSxt1laFXPZ-eHBWZkv4UK60d2BwgxCTbhUKalaHkrquvlWGru_r0xuaK_-Z7cHuT4EGr5MMEyUcGU_WOJjHSDw8lQSTF-rOcLj-UcykJBZGzPNxx-b58k2Qm0sV0Hr9wwvfhstUcuW0dVzT5QsHEGf7eQPUAiolMxCEQJrjPQ141jEhQk1t-iCxII7-GgrheDxtHUPkb1vF_E86h1B51O5POXe_hBLYVmpUXlsFOoZjNFuIMxXLmV3JcfgJpqJGK
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Anticorpo+monoclonal+isolado+anti-mol%C3%A9cula+de+orienta%C3%A7%C3%A3o+repulsiva+a&rft.inventor=Eve+H.+Barlow&rft.inventor=Hsieh+Chungming&rft.inventor=Bernhard+K.+M%C3%BCller&rft.inventor=Phillip+D.+Bardwell&rft.inventor=Schmidt+Martin&rft.inventor=Mary+R.+Leddy&rft.date=2022-03-15&rft.externalDBID=B1&rft.externalDocID=BR122012004341B1